, said study presenter Benjamin Solomon, MBBS, PhD, here at the 2024 American Society of Clinical Oncology annual meeting.These results, coupled with the absence of new safety signals, show that first-line lorlatinib provides an unprecedented improvement in outcomes for patients with+ NSCLC, added Solomon, head of Lung Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia, to a round of applause from meeting attendees.
The primary endpoint evaluation was stopped after 3 years but the patients continued to be followed, Solomon said. In the current post hoc 5-year analysis, the median duration of follow-up was 60.2 months in the lorlatinib arm and 55.1 months in the crizotinib arm. Delving deeper into the data, Solomon reported that lorlatinib was associated with a benefit compared with crizotinib regardless of whether patients had brain metastases at baseline — HR 0.08 in those with brain metastases, HR 0.24 in those without.
Finally, lorlatinib was associated with a progression-free survival benefit over crizotinib in patients with poor prognostic biomarkers, such as theDuring the press conference, David R. Spigel, MD, chief scientific officer at the Sarah Cannon Research Institute, Nashville, Tennessee, who was not involved in the study, noted that the PFS seen in the study was"outstanding."